Treatment
TCR-T cells clinical trials
We’re tracking 23 recruiting studies that include TCR-T cells, each written for real people, not researchers, below.
Recruiting studies
- NCT05483491RecruitingPhase 1
TCR cell therapy for select metastatic cancers
This Phase 1 trial tests a personalized immune-cell treatment (TCR-T cells) for certain metastatic cancers. It targets cancers that carry a specific marker and requires patients to have a specific immune-system match, aiming to improve cancer control when standard options were already tried.
New Brunswick, New JerseyAges 18 years+ - NCT07145450RecruitingPhase 1/Phase 2
T-cell therapy for advanced pancreatic cancer with KRAS mutations
This trial tests a personalized T-cell therapy designed to target pancreatic cancer cells that have a specific KRAS mutation (G12V or G12D). It is for people whose cancer has spread or is locally advanced and who have already benefited from standard treatments.
CopenhagenAges 18 years+ - NCT07467122RecruitingPhase 1
TCR-T cell therapy for MAGE-A4-positive sarcomas and other tumors
This trial tests a personalized cell therapy called TCR-T that targets a protein called MAGE-A4 on tumor cells. It is for people with advanced sarcomas or similar cancers that have not responded to standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT03778814RecruitingPhase 1
Personalized T-cell therapy for advanced lung or solid tumors
This Phase 1 study tests a lab-made immune cell treatment made from your own blood cells (T cells) to fight advanced lung cancer or other solid tumors. You may be eligible if your tumor can be biopsied and the lab can successfully prepare T cells that strongly recognize and attack your cancer.
Guanzhou, GuangdongAges 18–75 - NCT05438667RecruitingEarly Phase 1
T Cell therapy for solid tumors with specific KRAS and HLA types
This trial tests a personalized immune cell treatment made for people with advanced solid cancers that have not responded to standard care. It’s designed for tumors carrying a specific KRAS mutation (G12V or G12D) and for people whose immune “HLA type” matches the therapy.
Guangzhou, GuangdongAges 18 years+ - NCT05639972RecruitingPhase 1/Phase 2
HPV cancer trial using immune T cells made for you
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
New Brunswick, New JerseyAges 18 years+ - NCT05686226RecruitingPhase 2
Trial tests immune cells targeting HPV-16 cancers
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
Bethesda, MarylandAges 18 years+ - NCT06544720RecruitingPhase 1
SCG142 TCR-T cell therapy for HPV-related cancers
This trial tests a new treatment called SCG142 TCR-T cells for cancers caused by HPV. The therapy uses your own immune cells to fight the tumor. It may help if other treatments haven't worked or are not available.
Qingdao, ShandongAges 18 years+ - NCT07162012RecruitingEarly Phase 1
Cell therapy for EBV-positive lymphoma
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
ShanghaiAges 18–70 - NCT03891706RecruitingPhase 1
Personalized T-cell therapy for advanced solid tumors
This early-phase study tests personalized immune cells (T cells) made from your own tumor and blood to treat advanced solid cancers. It may help your immune system recognize and attack your tumor, especially if standard treatments no longer work.
Guangzhou, GaungdongAges 18–70 - NCT06487377RecruitingPhase 1
IX001 TCR-T for advanced KRAS-mutated pancreatic and colorectal cancer
This trial tests a new treatment called IX001 TCR-T, which uses your own immune cells to target cancer cells with a specific KRAS mutation. It's for people with advanced pancreatic or colorectal cancer who have run out of standard options.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06515314RecruitingPhase 1
TCR-T cell therapy for AFP-positive liver and other cancers
This trial tests an experimental cell treatment called HRYZ-T102 TCR-T for people with advanced liver cancer or other solid tumors that make a protein called AFP. The treatment uses your own immune cells, modified in a lab to target and kill cancer cells.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05881525RecruitingPhase 1
Testing NY-ESO-1 T-cell therapy for advanced solid tumors
This Phase 1 study tests a personalized immune therapy made from T cells to treat advanced solid cancers that carry a marker called NY-ESO-1. You may be able to join if your tumor shows the right NY-ESO-1 level and your body and lab tests can safely handle treatment.
ChongqingAges 18–70 - NCT06617000RecruitingPhase 1
Immune cell therapy for hepatitis B-related liver cancer
This study tests a new immune cell therapy (SCG101) for people with a certain type of liver cancer linked to hepatitis B. It's designed for those whose cancer has progressed after standard treatments.
Beijing, Beijing MunicipalityAges 18–70 - NCT05539833RecruitingEarly Phase 1
TCR-T cell therapy for HLA-A2 positive solid tumors
This early-phase study tests a personalized immune-cell treatment (TCR-T cells) made from your own immune cells. You may qualify if you have a solid tumor that shows a specific target on tumor cells and your body type (HLA-A2) matches what the therapy needs.
Nanning, GuangxiAges 18–70 - NCT05811975RecruitingEarly Phase 1
Personalized T-cell therapy for advanced solid tumors
This early-phase study tests a personalized treatment made from your own immune cells to attack solid tumors that have not responded to standard care. If you qualify, the team will collect blood cells, prepare the therapy, and give it back to you with close monitoring for safety and early signs of benefit.
Nanning, GuangxiAges 18–70 - NCT06885710RecruitingPhase 1
T cell therapy with antivirals for chronic hepatitis B
This study tests a new treatment that uses your own immune cells (T cells) modified to attack the hepatitis B virus, combined with standard antiviral medication. It is for people with chronic hepatitis B who have a specific HLA type and no advanced liver scarring.
ShanghaiAges 18–65 - NCT05620693Recruiting
Cell therapy study for NY-ESO-1–positive soft tissue cancer
This trial tests an engineered immune cell treatment (NY-ESO-1 TCR-T) for people with advanced soft tissue sarcoma that has returned or spread after standard treatment. It aims to treat cancer cells that show a specific marker (NY-ESO-1) in the tumor.
Shenzhen, GuangdongAges 18–70 - NCT06898385RecruitingPhase 1
IX001 TCR-T Cells for Advanced Pancreatic Cancer with KRAS G12V
This trial tests a new treatment called IX001 TCR-T cells, which are specially designed immune cells that target a specific mutation (KRAS G12V) found in some pancreatic cancers. It is for people whose cancer has not been controlled by standard chemotherapy.
Guangzhou, GuangdongAges 18–75 - NCT06942143RecruitingPhase 1
Super1 TCR-T for NY-ESO-1 positive advanced solid tumors
This trial tests an experimental treatment called Super1 TCR-T, which is a type of immunotherapy designed to attack tumors that have a specific protein (NY-ESO-1). It is for people with advanced solid tumors whose first treatment has stopped working and who also have a certain genetic marker (HLA-A*02).
Guangzhou, GaungdongAges 18–75 - NCT06119256RecruitingPhase 1
TCR-T cells for EBV after stem cell transplant
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
Beijing, Beijing MunicipalityAges 14–75 - NCT06135922RecruitingPhase 1
EBV-TCR-T cells for EBV-related HLH or infection
This trial tests a new immune cell therapy (EBV-TCR-T cells) for people with a severe immune reaction caused by the Epstein-Barr virus (EBV-HLH) or active EBV infection. The treatment uses special cells from a matched donor to help your body fight the virus.
Beijing, Beijing MunicipalityAges 1–60 - NCT06170294RecruitingPhase 1
MAGE-A4 TCR-T therapy for advanced solid tumors
This trial tests a new type of immune therapy called MAGE-A4-directed TCR-T. It uses your own immune cells (T cells) that are modified to find and attack cancer cells that have a specific protein (MAGE-A4). It is for people with advanced solid tumors who have already tried other treatments.
Beijing, Beijing MunicipalityAges 18–75
What TCR-T cells is being studied for
Conditions with recruiting TCR-T cells studies.
Common questions
- Are there clinical trials studying TCR-T cells?
- Yes. Clin2 currently lists 23 recruiting studies that include TCR-T cells, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a TCR-T cells trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is TCR-T cells an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether TCR-T cells or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.